Digital Therapeutics DTX for Mental Health Market Global Report 2026

The digital therapeutics DTX for mental health market size has grown exponentially in recent years. It will grow from $4.76 billion in 2025 to $5.82 billion in 2026 at a compound annual growth rate (CAGR) of 22.2%. The growth in the historic period can be attributed to limited access to traditional psychiatric care services, high stigma associated with mental health treatment, low penetration of digital health platforms in mental healthcare, reliance on in-person therapy sessions, lack of scalable mental health treatment options.

The digital therapeutics DTX for mental health market size is expected to see exponential growth in the next few years. It will grow to $12.77 billion in 2030 at a compound annual growth rate (CAGR) of 21.7%. The growth in the forecast period can be attributed to rising global prevalence of mental health disorders, increasing acceptance of digital mental health solutions, expansion of insurance coverage for digital therapeutics, growing integration of AI-driven personalized therapy models, stronger regulatory validation of clinically approved digital therapeutics. Major trends in the forecast period include increasing adoption of AI-powered conversational therapy bots for real-time mental health support, growth of mobile-based digital cognitive behavioral therapy applications for anxiety and depression management, rising use of personalized digital therapeutics platforms for condition-specific psychiatric treatment, expansion of remote patient monitoring tools for continuous mental health tracking, increasing integration of gamified neurocognitive training modules for engagement-driven therapy adherence.

The increasing prevalence of mental health disorders is expected to drive the growth of the digital therapeutics (DTx) for mental health market in the coming years. Mental health disorders are clinically recognized conditions that impact emotional well-being, cognitive abilities, and behavioral functioning, often reducing an individual’s social and workplace performance. The growing prevalence of these disorders is largely attributed to rising chronic stress levels resulting from economic instability, social isolation, and high-pressure work environments. Digital therapeutics (DTx) for mental health provide evidence-based therapeutic interventions designed to monitor, manage, and treat mental health conditions. For example, in May 2024, according to the American Psychiatric Association, a US-based non-profit organization, 43% of adults reported higher levels of anxiety in 2024, compared with 37% in 2023 and 32% in 2022. Therefore, the increasing prevalence of mental health disorders is fueling the growth of the digital therapeutics (DTx) for mental health market.

Major companies operating in the digital therapeutics (DTx) for mental health market are focusing on developing advanced digital therapeutics solutions, such as prescription digital therapeutics, to improve depression management, enhance patient engagement, and expand access to evidence-based mental healthcare. Prescription digital therapeutics are software-based clinical treatment solutions prescribed by healthcare professionals to prevent, manage, or treat medical and mental health conditions through validated therapeutic interventions. For instance, in August 2024, Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched Rejoyn, the first FDA-cleared prescription digital therapeutic for adjunctive treatment of major depressive disorder symptoms in adults aged 22 years and older who are already receiving antidepressant medication. The smartphone-based application combines cognitive emotional training with evidence-based therapeutic lessons to support depression treatment and improve long-term patient outcomes.

In July 2023, Big Health Inc., a US-based digital therapeutics company, acquired Limbix Health Inc. for an undisclosed amount. Through this acquisition, Big Health Inc. aimed to expand its digital mental health portfolio for adolescents and young adults by integrating Limbix Health Inc.’s prescription digital therapeutic platform, SparkRx, to strengthen evidence-based treatment solutions for depression and behavioral health conditions. Limbix Health Inc. is a US-based prescription digital therapeutics company that develops software-based mental health treatment solutions for adolescents and young adults with depression and behavioral health conditions.

Major companies operating in the digital therapeutics dtx for mental health market are Teladoc Health Inc.; Omada Health Inc.; NOCD Inc.; Brightside Health Inc.; Orexo AB; Otsuka Pharmaceutical Co. Ltd.; Click Therapeutics Inc.; Big Health Ltd.; WellDoc Inc.; Woebot Health Inc.; Holmusk Pte. Ltd.; Meru Health Inc.; CogniFit Inc.; Freespira Inc.; 2Morrow Inc.; GAIA AG; Limbic AI Ltd.; MindNet GmbH.

North America was the largest region in the digital therapeutics (DTx) for mental health market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics DTX for mental health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital therapeutics DTX for mental health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The digital therapeutics (DTx) for mental health market includes revenues earned by entities by providing services such as software-based therapeutic services, AI-enabled mental healthcare solutions, virtual psychiatric support services, and remote patient monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The digital therapeutics dtx for mental health market research report is one of a series of new reports that provides digital therapeutics dtx for mental health market statistics, including digital therapeutics dtx for mental health industry global market size, regional shares, competitors with a digital therapeutics dtx for mental health market share, detailed digital therapeutics dtx for mental health market segments, market trends and opportunities, and any further data you may need to thrive in the digital therapeutics dtx for mental health industry. This digital therapeutics dtx for mental health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.